BOSTON (S&P Global Ratings) Nov. 5, 2026--S&P Global Ratings today assigned its'BBB'issue-level rating to Zimmer Biomet Holdings Inc.'s proposed dollar- and euro-denominated senior unsecured notes, which it will issue in two tranches (amounts and maturities to be determined). The company will use the net proceeds from these notes for general corporate purposes, which may include repaying debt, financing capital commitments, and funding future acquisitions and share repurchases. Our'BBB'issuer credit rating and stable outlook on Zimmer Biomet are unchanged. Despite a reduction in knee implant sales, headwinds in China, and pricing pressures in the third quarter, the company solidly increased its reported revenue by 3.7% on constant-currency basis relative to the prior year period. Zimmer also raised
